Evidence map›Paper›PMID 29844389›Full record

ArticleScientific reports2018

Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice.

Sara L Dominguez, Ganapati V Hegde, Jesse E Hanson, Hong Xiang, Danielle Mandikian, C Andrew Boswell, Cecilia Chiu, Yan Wu, Siao Ping Tsai, Daniel Fleck and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sara L DominguezGenentech, Neuroscience, South San Francisco, 94080, USA.
Ganapati V HegdeGenentech, Discovery Oncology, South San Francisco, 94080, USA.
Jesse E HansonGenentech, Neuroscience, South San Francisco, 94080, USA.
Hong XiangGenentech, Developmental Sciences, South San Francisco, 94080, USA.
Danielle MandikianGenentech, Developmental Sciences, South San Francisco, 94080, USA.
C Andrew BoswellGenentech, Developmental Sciences, South San Francisco, 94080, USA.
Cecilia ChiuGenentech, Antibody Engineering, South San Francisco, 94080, USA.
Yan WuGenentech, Antibody Engineering, South San Francisco, 94080, USA.
Siao Ping TsaiGenentech, Biochemical and Cellular Oncology, South San Francisco, 94080, USA.
Daniel FleckGenentech, Neuroscience, South San Francisco, 94080, USA.
Martin WeberGenentech, Neuroscience, South San Francisco, 94080, USA.
Hai NguGenentech, Pathology, South San Francisco, 94080, USA.
Kimberly Scearce-LevieGenentech, Neuroscience, South San Francisco, 94080, USA.
Erica L JacksonGenentech, Discovery Oncology, South San Francisco, 94080, USA. erica@oricpharm.com.
Sunesis (United States) · USDenali Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuregulin 1 (NRG1) is required for development of the central and peripheral nervous system and regulates neurotransmission in the adult. NRG1 and the gene encoding its receptor, ERBB4, are risk genes for schizophrenia, although how alterations in these genes disrupt their function has not been fully established. Studies of knockout and transgenic mice have yielded conflicting results, with both gain and loss of function resulting in similar behavioral and electrophysiological phenotypes. Here, we used high affinity antibodies to NRG1 and ErbB4 to perturb the function of the endogenous proteins in adult mice. Treatment with NRG1 antibodies that block receptor binding caused behavioral alterations associated with schizophrenia, including, hyper-locomotion and impaired pre-pulse inhibition of startle (PPI). Electrophysiological analysis of brain slices from anti-NRG1 treated mice revealed reduced synaptic transmission and enhanced paired-pulse facilitation. In contrast, mice treated with more potent ErbB4 function blocking antibodies did not display behavioral alterations, suggesting a receptor independent mechanism of the anti-NRG1-induced phenotypes. We demonstrate that anti-NRG1 causes accumulation of the full-length transmembrane protein and increases phospho-cofilin levels, which has previously been linked to impaired synaptic transmission, indicating enhancement of non-canonical NRG1 signaling could mediate the CNS effects.

Indexed as

Actin Depolymerizing FactorsAnimalsAntibodies, BlockingCentral Nervous SystemDisease Models, AnimalElectrophysiologyGenetic Predisposition to DiseaseHEK293 CellsHumansMiceMice, Inbred C57BLNeuregulin-1Protein StabilityReceptor, ErbB-4RiskSchizophreniaActin Depolymerizing FactorsAntibodies, BlockingErbb4 protein, mouseNeuregulin-1Receptor, ErbB-4

Identifiers

PMID29844389
PMCPMC5974084
OpenAlexW2805206167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.